Clinical Analysis of Hematologic Monitoring in Chemotherapy for Patients with Gynecologic Cancer

Kim, S H; Kim, E S; Jin, K S; Lee, B Y; Lee, S K; Huh, J Y; Kim, S B

Abstract

Anticancer chemotherapy has important role in gynecologic cancer treatment and the use of combination chemotherapy in which two or more drugs are combined, has been increased. 64 gynecologic cancer patients who treated with combination anticancer chemotherapy were reviewed retrospectively in this study for the evaluation of drug toxicity by using hematologic monitoring. THE RESULTS WERE AS FOLLOWS: 1. Leukocyte count was the most important parameter in the bone marrow toxicity. And granulocyte and platelet count must be monitored if leukocytopenia is developed. 2. Considering the severe drug toxicity over grade 3, leukopenia in VBP(Vinblastine, Bleomycin, Cis-platin), CAP(Cyclophosphamide, Adriamycin, Cis-platin), CDDP-5FU (Cis-platin, 5-Fluorouracil) were 8 cases(32%), 3 cases(23%), and 3 cases(20%) respectively. And severe thrombocytopenia in VBP, CAP, and CDDP-5FU were 2 cases(7%), 1 cases(8%), and 1 cases(6%) respectively. Severe anemia was 3 cases(23%) in CAP, and hepatotoxicity was 1 cases(14%) in CP(Cyclophosphamide, Cis-platin) chemotherapy. 3. Concerning the VBP, CAP and CDDP-5FU regimen, there was no significant correlation between the number of cycle and the changes of hematologic variables especially leukocyte and platelet count. So it is difficult to predict the time of severe myelosuppression with hematologic evaluation alone. Follow up hematologic monitoring with regular interval may be useful for the early detection of myelosuppression.